AMPE Ampio Pharmaceuticals Inc.

0.4
-0.04  -10%
Previous Close 0.44
Open 0.45
Price To Book 20
Market Cap 42697278
Shares 106,716,516
Volume 1,194,292
Short Ratio 11.97
Av. Daily Volume 1,750,071

SEC filingsSee all SEC filings

  1. 8-K - Current report 181229983
  2. 8-K - Current report 181224817
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181180200
  4. DEF 14A - Other definitive proxy statements 181148598
  5. 8-K - Current report 181106875

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Noted August 7, 2018 that further trials required before filing BLA, confirmed December 13, 2018.
Ampion
Osteoarthritis of the Knee
Phase 2b data released May 2015 did not meet endpoints
Optina
Diabetic Macula Edema

Latest News

  1. Ampio Updates Regulatory Status for Ampion
  2. Ampio Updates Regulatory and Publication status for Ampion™
  3. 3 Health Care Stocks Rallying After US Midterms
  4. Ampio Updates Regulatory and Clinical Status for Ampion™
  5. Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Ampio Pharmaceuticals, Inc. (AMPE) and Encourages AMPE Investors to Contact the Firm
  6. Factors of Influence in 2018, Key Indicators and Opportunity within Intersect ENT, Akari Therapeutics, Ampio Pharmaceuticals, Virtusa, Umpqua, and Hamilton Lane — New Research Emphasizes Economic Growth
  7. DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  8. CLASS ACTION UPDATE for AMPE, ALNY and CHGG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  9. Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ampio Pharmaceuticals, Inc.
  10. SHAREHOLDER ALERT: AMPE LCI PZZA SKX PM USAT COCP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
  11. WEDNESDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  12. FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ampio Pharmaceuticals, Inc. (AMPE) and Lead Plaintiff Deadline – October 24, 2018
  13. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Ampio Pharmaceuticals, Inc. To Contact The Firm
  14. DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  15. CLASS ACTION UPDATE for AMPE, ALNY and HTHT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  16. 2-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Ampio Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
  17. LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Ampio Pharmaceuticals, Inc. to Contact The Firm
  18. SHAREHOLDER ALERT: AMPE NVRO PZZA OPK QRTEA MCHP COCP TGTX CPB TRVN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

SEC Filings

  1. 8-K - Current report 181229983
  2. 8-K - Current report 181224817
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181180200
  4. DEF 14A - Other definitive proxy statements 181148598
  5. 8-K - Current report 181106875
  6. 8-K - Current report 181103040
  7. 8-K - Current report 181053442
  8. SC 13G - Statement of acquisition of beneficial ownership by individuals 181024779
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 181013768
  10. 8-K - Current report 181010185